McDermott and Bull executive Search
 

Other News

Philips introduces Advanced Image Insights for advanced visualization and AI orchestration

Advanced Image Insights

Advanced Image Insights

Advanced Visualization Workspace

Advanced Visualization Workspace

November 19, 2026 Cloud-based solution brings advanced clinical tools and AI insights into radiology workflows, connecting image analysis with interactive reporting Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Philips Advanced Image Insights on HealthSuite [1], a cloud-based solution combining Philips advanced visualization applications with centralized management and orchestration of third-party AI applications for imaging. Connected to Philips HealthSuite Imaging, the solution enables workflow automation and delivers analysis results, produced by advanced visualization and AI applications, into existing radiology workflows. These results can also be incorporated into structured multimedia reports using Philips Interactive Reporting Assistant, helping streamline the radiology workflow from images to report and supporting diagnostic decisions. At RSNA 2026 in Chicago, Philips will showcase Advanced Image Insights as a key innovation in its Healthcare Informatics portfolio, demonstrating how advanced visualization and AI orchestration support radiologists and how Philips brings imaging systems, software, data, AI and services together through open platforms that connect people, information and care settings. Radiology teams face growing imaging volumes, increasingly complex studies and continued workforce pressures. While advanced visualization and AI can help uncover deeper clinical insights, managing a growing number of disconnected applications can add complexity and manual work. This can make it harder to keep images, analysis results, clinical findings and reports connected throughout the diagnostic workflow. “The opportunity in radiology isn’t simply to add more AI applications, but to make intelligence work better across the diagnostic journey,” said Madhuri Sebastian, Business Leader Imaging Informatics at Philips. “By connecting advanced visualization tools and AI applications, we can help reduce manual steps and give clinicians the insights and context they need to make confident care decisions. This can help give care teams more time to apply their expertise where it matters most when reviewing images and application results, providing better care for more people.” Bringing advanced visualization and AI into the diagnostic workflowAdvanced Image Insights provides access to advanced applications and AI-enabled analysis tools across supported imaging modalities, clinical specialties and sites. Connected to Philips HealthSuite Imaging PACS, intelligent application automation supports the transfer of clinical analysis tools directly into the PACS for radiologists to review alongside diagnostic images. Philips Interactive Reporting Assistant brings findings, key images and AI results together in structured multimedia reports with hyperlinks, tables and graphs, making results easy to access. Built-in voice recognition, automatic template selection and data population streamline report creation, reducing repetitive documentation and manual data transfer. For example, during a lung CT workflow, AI applications can analyze images in the background for signs of incidental pulmonary embolism, while other applications can support quantitative lung nodule assessment. Through Advanced Image Insights, the results can be made available within the clinical workflow for the radiologist to review alongside the images to support efficient review and reporting. Radiologists remain responsible for reviewing images and AI outputs and making the final interpretation, while referring clinicians can benefit from additional context for diagnosis and treatment planning and patient follow-up. Extending access across the enterprise Delivered as a managed software-as-a-service offering on Philips HealthSuite, powered by Amazon Web Services (AWS), Advanced Image Insights enables remote access to advanced analysis tools. Philips manages the underlying infrastructure and operations, helping reduce IT burden and support expansion across sites and subspecialties. See Advanced Image Insights at RSNA 2026Philips innovations help simplify workflows and support confident diagnostic decisions, giving care teams more time to apply their expertise where it matters most and helping more patients get confident diagnosis and treatment faster. Attendees can learn more at the Philips booth #6730 and here. [1] Advanced Image Insights is a cloud-managed solution that provides a single point of access to Philips and third-party applications. Each application retains its own intended use and regulatory status. Availability of the solution and individual applications varies by market. Please contact a Philips representative for details. For further information, please contact: Anna HogrebePhilips Global External RelationsTel.: +1 416 270 6757E-mail: Anna.Hogrebe@philips.com About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.  Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,900 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. 

Attachments

Advanced Image Insights

Advanced Visualization Workspace

SS Innovations Announces World’s First Dual-Console, Beating-Heart TECAB Surgery Utilizing All Five Arms of the SSi Mantra Surgical Robotic System

World’s First Dual-Console, Beating-Heart TECAB Surgery Utilizing All Five Arms of the SSi Mantra

Dr. Rajput and Dr. Malik performing the world’s first dual-console, beating-heart TECAB surgery utilizing all five arms of the SSi Mantra at Medanta Hospital in Gurugrum, India

Landmark procedure successfully performed at Medanta Hospital in Gurugram, India, demonstrating the power of dual-console technology in complex robotic cardiac surgeries   FORT LAUDERDALE, Fla., Nov. 19, 2026 (GLOBE NEWSWIRE) — via IBN – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that a team of surgeons successfully completed the world’s first dual-console, beating-heart Totally Endoscopic Coronary Artery Bypass (“TECAB”) surgery utilizing all five arms of the Company’s SSi Mantra surgical robotic system (the “SSi Mantra”) at Medanta – The Medicity Hospital (“Medanta Hospital”) in Gurugram, India. Dr. Nitin Kumar Rajput of Medanta Hospital and Dr. Lalit Malik of Manipal Hospital, Jaipur, successfully performed the beating-heart TECAB procedure using two separate consoles and the SSi Mantra, under the guidance of Dr. Sudhir Srivastava, the Company’s Chairman of the Board and Chief Executive Officer.  The two surgeons completed the complex cardiac procedure using all five of the SSi Mantra’s arms simultaneously, in complete synchronization, under a dual-console configuration.  A heart stabilization system steadied the target area while the patient’s heart continued to beat. TECAB surgery is a highly complex form of a coronary artery bypass procedure performed through small incisions, without opening the chest, unlike a conventional sternotomy. The beating-heart approach allows surgeons to perform the bypass while the heart continues to beat, without using a heart-lung machine. Combining this technique with a five-arm robotic configuration under dual-console control marks a significant advancement in the application of robotics to minimally invasive cardiac surgery.   For video highlights of the dual-console, beating-heart TECAB surgery, please visit: link.  Dr. Srivastava commented, “The successful use of dual-console control and five robotic arms in a beating-heart TECAB procedure demonstrates the advanced capabilities of the SSi Mantra in enabling complex minimally invasive cardiac surgeries.  Our mission at SS Innovations is to democratize access to world-class robotic surgery, including the most intricate cardiac procedures, and this achievement brings us a step closer to that goal.” Dr. Naresh Trehan, Chairman and Managing Director of Medanta Hospital, said, “I am delighted to share with you that we have performed the first coronary bypass surgery using the SSi Mantra robot where we have used five arms and a dual console.  This is the first time that this has been done in the world, and the patient is doing extremely well.  The robot, and the whole procedure went marvelously, and everything went according to schedule.  I believe that this innovation by Dr. Sudhir Srivastava and his team at SS Innovations has really transformed the way we will do robotic surgery in the future.  Today is a landmark day from our point of view.” Dr. Rajput said, “Performing a complex beating-heart bypass procedure using five robotic arms and two control consoles requires precision, coordination and close collaboration between the surgeons. This approach allowed us to work in synchronization throughout the procedure. The patient’s recovery following surgery was encouraging and reinforces the potential of minimally invasive robotic techniques in advancing cardiac care.” Dr. Malik added, “This procedure marks an important step in the evolution of robotic cardiac surgery. The dual-console setup enabled coordinated control between the two surgeons, while the five-arm configuration supported the technical demands of the operation. Such advancements can help expand the possibilities of minimally invasive cardiac procedures and improve the overall surgical experience for patients.” For a video message from Dr. Srivastava, please visit: link. For a video message from Dr. Trehan, please visit: link. About SS Innovations SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures, including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi MantraThe SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch-panel monitor for displaying all patient-related information, a virtual real-time image of the robotic patient-side arm carts, and the ability to superimpose 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5 mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures. Forward-Looking StatementsThis press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investor Contact:The Equity Group        Kalle Ahl, CFA              T: (303) 953-9878        kalle.ahl@theequitygroup.com Devin Sullivan, Managing Director T: (212) 836-9608devin.sullivan@theequitygroup.com Media Contact:RooneyPartners LLCKate BarretteT: (212) 223-0561kbarrette@rooneypartners.com
Attachment

World’s First Dual-Console, Beating-Heart TECAB Surgery Utilizing All Five Arms of the SSi Mantra

Conavi Medical Highlights Commercial Launch and Significant Growth Potential in Shareholder Letter

FDA clearance and ongoing U.S. clinical use establish a platform for OCTIV™ growthTORONTO, Nov. 19, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today issued the following letter to shareholders from Thomas Looby, President and Chief Executive Officer. Dear Shareholders, Years of development have now translated into U.S. commercial clinical use. Over the past year, Conavi achieved four milestones that establish the foundation for OCTIV™, powered by Novasight™: FDA 510(k) clearance for our next-generation hybrid imaging system.Peer-reviewed clinical evidence illustrating how hybrid imaging can inform coronary treatment decisions.First U.S. commercial placement and clinically beneficial cases with OCTIV, followed by ongoing use by multiple physicians.Five-year extension of the Japan Lifeline credit facilities, moving maturity from April 2027 to April 2032. Together, these achievements position Conavi to broaden physician adoption, expand hospital placements, grow recurring catheter utilization and attract strategic interest in our platform. Clinical Evidence Supports Broader Adoption OCTIV combines the imaging depth of intravascular ultrasound (“IVUS”) with the high-resolution detail of optical coherence tomography (“OCT”) in a single catheter to guide coronary interventions. The 2025 U.S. acute coronary syndrome guidelines give IVUS or OCT a Class 1, Level of Evidence A recommendation for procedural guidance in patients with acute coronary syndromes undergoing stent implantation in the left main artery or complex lesions. Pooled randomized evidence shows lower risks of cardiac death, heart attacks, repeat interventions and stent thrombosis with intravascular imaging guidance than with angiography alone. Our peer-reviewed case reports illustrate how hybrid imaging can inform treatment decisions: July case report. In the Journal of the Society for Cardiovascular Angiography & Interventions, physicians described using hybrid imaging to assess and treat a calcified lesion in a patient with impaired renal function, with IVUS-only imaging at selected stages helping to limit contrast exposure.September case report. In Catheterization and Cardiovascular Interventions, hybrid imaging helped physicians evaluate post-stent dissections and white thrombus, informing decisions on further stenting and medical management. OCTIV Is in Ongoing Clinical Use In November, we announced our first U.S. commercial placement and clinical cases, with Dr. Megha Prasad performing the initial cases. Approximately 25 clinical cases have been completed within the first two weeks of launch. Successful cases are continuing, with multiple physicians on the hospital’s team now using OCTIV. OCTIV incorporates enhancements focused on image quality, catheter deliverability and ease of use. Its patient interface module sits outside the sterile field, and the catheter connection workflow is designed to simplify setup. Strong Physician Demand Following Launch and TCT Following our first U.S. clinical cases, we participated in Transcatheter Cardiovascular Therapeutics (“TCT”) 2026, where OCTIV received a strong reception. Clinical presentations and physician education sessions introduced its complementary imaging capabilities to a broader audience. Demand for OCTIV systems now exceeds our current placement capacity. The response to our limited market release and initial clinical experience, as well as discussions at TCT have surfaced strong demand for OCTIV systems. We will work to meet this demand over time. We also presented preclinical saline-based imaging results: 26 interpretable imaging pullbacks in three swine, without iodinated contrast during image acquisition. These findings support further evaluation of an approach that could help physicians manage contrast exposure. Financial Flexibility Supports Commercial Expansion Japan Lifeline support. Backed by a relationship spanning more than a decade, the five-year extension better aligns our debt maturity with our commercial development plans.$1.75 million received under Ontario’s Life Sciences Scale-Up Fund, including a $1.25 million payment following FDA clearance. The agreement provides up to $2.5 million, subject to specified milestones, for eligible commercialization and manufacturing activities. Our spending priorities are physician support, additional sites, reliable product supply and clinical evidence. Clear Priorities for Growth Our first U.S. placement and ongoing clinical cases are meeting and exceeding our expectations. Our priority now is to supply this strong, initial demand through carefully selected hospital placements, physician education and support for repeat use. Four priorities will guide our execution: Prioritize the next U.S. placements. Focus on hospitals where physician demand, procedural needs and operational readiness align.Grow catheter utilization. Build on ongoing use at our first U.S. site by supporting repeat procedures and training additional physicians.Generate clinical evidence. Build on our initial commercial cases and peer-reviewed reports to support further publications showing how hybrid imaging informs treatment decisions.Expand physician education and market awareness. Follow up on TCT discussions with targeted education, scientific meetings and direct engagement to help interested clinical teams integrate OCTIV into their workflows. Building a Sustainable Commercial Business This year, the essential pieces came together: regulatory clearance, published clinical evidence, ongoing U.S. commercial use and greater financial flexibility. We now have a clear foundation for growth. We believe disciplined execution can strengthen Conavi’s commercial position, attract strategic interest in our platform and create lasting shareholder value. To our employees, clinical collaborators, partners and shareholders, thank you for helping bring Conavi to this point. We look forward to sharing our progress as we expand OCTIV’s clinical and commercial reach. Sincerely,Thomas LoobyPresident and Chief Executive OfficerConavi Medical Corp. About Conavi MedicalConavi Medical Corp. is a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures. Its OCTIV™ hybrid imaging system combines intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) to provide simultaneous, co-registered images of coronary arteries using a single imaging catheter. These complementary imaging modalities provide physicians with information to support treatment decisions during coronary interventions. For more information, visit www.conavi.com. Forward looking informationThis press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the anticipated clinical benefits and performance of OCTIV, continued clinical use, placements at additional U.S. institutions, plans to expand physician adoption, system utilization and recurring catheter revenue, the potential to attract strategic interest, further evaluation of saline-based hybrid imaging, the anticipated benefits of the credit facility maturity extension, the continued commercialization and U.S. rollout of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to execute its commercial development plans, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. ContactMark Quick, Chief Financial Officer | 416-483-0100Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.comSusan Thomas, Media | 619-540-9195

Hyland logo new

New Diagnostic Radiology from Hyland Meets Growing Demand for Medical Image Reading and Management with Intelligent, Scalable Workflows

Imaging demand is projected to rise approximately 17% for MRI and 25% for CT by 2055, even as the radiologist workforce is projected to reach only 90% of needed capacity by 2038, leaving hiring alone unable to close the gap A 2026 JACR analysis of 46.4 million examinations found the most…

Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

IPO completed in October 2026 to support the continued development of RTN-001 for uncontrolled and resistant hypertension, affecting ~30 million AmericansUpsized IPO generated $51.75 million in gross proceedsTopline data for Phase 2b clinical trial expected in first half of 2027 FALLS CHURCH, Va., Nov. 18, 2026 (GLOBE NEWSWIRE) — Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. “Completing our initial public offering was an important step for Retension, and it provides the capital to complete our Phase 2b clinical trial of RTN-001 and prepare for Phase 3,” said Eric Keller, Chief Executive Officer of Retension Pharmaceuticals. “This year we have also built a leadership team with deep experience advancing cardiovascular and metabolic therapies from clinical development through approval, and formed a Scientific Advisory Board of leading investigators in hypertension, cardiology and nephrology. We remain focused on executing the Phase 2b trial, with initial data expected in the first half of 2027, as we work to bring a new treatment option to patients with uncontrolled and resistant hypertension.” Recent Corporate Highlights and Upcoming Milestones Completed initial public offering: In October 2026, Retension completed its upsized initial public offering of 4,312,500 shares of common stock at $12.00 per share, which includes the full exercise of the underwriters’ option to purchase 562,500 additional shares. The offering generated gross proceeds of $51.75 million and net proceeds of approximately $45.1 million. Retension’s common stock began trading on the Nasdaq Capital Market under the ticker symbol “RTSN” on October 9, 2026. Phase 2b clinical trial of RTN-001 ongoing: The randomized, placebo-controlled, dose-ranging trial is evaluating RTN-001 in approximately 280 patients with uncontrolled hypertension. The study’s primary endpoint is the change from baseline in office-seated systolic blood pressure at Week 4 versus placebo. The trial will also inform dose selection for Phase 3. Topline data are expected in the first half of 2027. Strengthened executive leadership team: Alison D. Schecter, M.D., FACC, FCCP, Chief Medical Officer: Oversaw three hypertension registration trials at Mineralys TherapeuticsAlex Schwartz, Chief Financial Officer: Joined from Ventyx Biosciences, where he led financial planning and investor relationsLeAnne Bloedon, M.S., RD, Executive Vice President, Clinical Development and Operations: Former Head of Development at Esperion TherapeuticsKevin Schutz, PharmD, Vice President, Regulatory Affairs: Joined from Corxel Pharmaceuticals, where he served as Vice President, Global Regulatory AffairsRobert Wong, Vice President, Chief Accounting Officer: Joined from Save Mart, where he was Vice President of Accounting; previously Vice President, Chief Accounting Officer of Cytokinetics and Controller and Chief Accounting Officer of Genentech Added biopharma and cardiovascular leadership to the Board of Directors: Pavan Cheruvu, M.D., Director: Chief Executive Officer of Amanat Acquisition Corp.; former President and CEO of Bitterroot Bio and President, CEO, and Chief R&D Officer of Sio Gene Therapies; early member of the Roivant Sciences executive team Formed Scientific Advisory Board. Bringing together leading investigators in hypertension, cardiology and nephrology: Omar Al Dhaybi, M.D., MSc, FASN, Director, American Heart Association Comprehensive Hypertension Center, Mount Sinai Fuster Heart Hospital; Assistant Professor of Medicine, Icahn School of Medicine at Mount SinaiJames L. Januzzi, M.D., Adolph Hutter Professor of Medicine, Harvard Medical School; Massachusetts General Hospital; Chief Scientific Officer, Baim Institute for Clinical ResearchLuke J. Laffin, M.D., Preventive Cardiology, Cleveland Clinic; Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Chair, Steering Committee for Retension’s Phase 2b trialIan Wilkinson, M.D., Professor of Therapeutics and Director, Cambridge Clinical Trials Unit, University of Cambridge; President, British and Irish Hypertension SocietyRandall M. Zusman, M.D., Director, Division of Hypertension, Massachusetts General Hospital Heart Center; Associate Professor of Medicine, Harvard Medical School Third Quarter 2026 Financial Results Cash position: Cash and cash equivalents were $9.2 million as of September 30, 2026, compared to $18.9 million as of December 31, 2025. These amounts do not reflect the net proceeds of the IPO, which closed after quarter-end. Including net IPO proceeds of approximately $45.1 million, pro forma cash and cash equivalents as of September 30, 2026 were approximately $54.3 million.Research and development expenses: Research and development expenses were $5.0 million for the third quarter of 2026, compared to $1.4 million for the third quarter of 2025. The increase was primarily due to Phase 2b clinical trial costs.General and administrative expenses: General and administrative expenses were $1.0 million for the third quarter of 2026, compared to $0.3 million for the third quarter of 2025. The increase was primarily due to higher personnel costs.Net loss: Net loss was $5.9 million for the third quarter of 2026, compared to a net loss of $1.5 million for the third quarter of 2025 due to additional R&D and G&A expenses. About Retension Pharmaceuticals Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company’s lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension. About RTN-001 Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor designed to directly enhance nitric oxide signaling in central arteries not adequately reached by first-generation PDE5 inhibitors, thereby addressing a core driver of hypertension. RTN-001 has been studied in multiple clinical trials totaling 265 subjects. RTN-001 has a demonstrated efficacy and safety profile in patients and healthy volunteers with clinically meaningful reductions in blood pressure. A Phase 2b trial of RTN-001 in hypertension is ongoing. RTN-001 is being developed under an exclusive world-wide license from Sanofi S.A. For more information, please see www.retensionpharmaceuticals.com. Special Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including, but not limited to, statements regarding the Company’s expected cash runway, the use of proceeds from its initial public offering, and the design, progress, timing and results of its Phase 2b clinical trial of RTN-001, and other statements regarding Retension’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on Retension’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, therefore you should not place undue reliance on these forward-looking statements. The words, including but not limited to, “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “shall,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions are intended to identify these forward-looking statements. Retension’s actual results may differ materially from those expressed in, or implied by, such forward-looking statements due to a number of factors, including but not limited to, risks, uncertainties, assumptions and other factors described in the Company’s final prospectus filed with the U.S. Securities and Exchange Commission (“SEC”) on October 9, 2026 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as well as other documents that may be filed by the Company from time to time with the SEC. Retension undertakes no obligation to update any forward-looking statements after the date of this press release or to conform such statements to actual results or revised expectations, except as required by law. Contact: Press and Investor ContactAlex SchwartzChief Financial Officerinvestors@retensionpharmaceuticals.com RETENSION PHARMACEUTICALS, INC.Condensed Consolidated Statements of Operations (Unaudited)   For the Three Months Ended For the Nine Months Ended  September 30, September 30,  2026 2025 2026 2025Operating Expenses        Research & development $5,016,602  $1,365,256  $11,219,240  $2,542,254 General and administrative  990,759   299,574   2,574,495   1,231,791 Total Operating Expenses  6,007,361   1,664,830   13,793,735   3,774,045 Loss from Operations  (6,007,361)  (1,664,830)  (13,793,735)  (3,774,045)Other Income (Expense)            Exchange loss  —   —   (856)  — Interest income  89,277   189,016   351,457   412,558 Total Other Income  89,277   189,016   350,601   412,558 Net Loss $(5,918,084) $(1,475,814) $(13,443,134) $(3,361,487)Net loss per share – Basic and diluted $(7.33) $(1.83) $(16.65) $(4.17)Weighted-average common shares outstanding -Basic and diluted  807,894   805,154   807,287   805,154  Condensed Consolidated Balance Sheets     December 31,  September 30, 2026 2025  (unaudited) (As Restated)Assets    Current Assets    Cash and cash equivalents $9,190,083  $18,901,024 Prepaid expenses and other current assets  2,470,521   2,346,077 Deferred offering costs  2,487,892   198,060 Total Current Assets  14,148,496   21,445,161 Total Assets  14,148,496   21,445,161 Liabilities, Preferred Stock and Stockholders’ Deficit      Current Liabilities      Accounts payable  3,886,011   775,859 Accrued expenses  2,772,818   136,307 Total Current Liabilities  6,658,829   912,166 Total Liabilities  6,658,829   912,166 Commitments and Contingencies      Convertible Preferred Stock  28,153,769   28,315,918 Stockholders’ Deficit      Common stock  81   81 Additional paid-in-capital  1,094,140   532,185 Accumulated deficit  (21,758,323)  (8,315,189)Total Stockholders’ Deficit  (20,664,102)  (7,782,923)Total Liabilities, Preferred Stock and Stockholders’ Deficit $14,148,496  $21,445,161 

Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026

Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol control with reduced treatment burden; repeat dosing in NHPs enabled further LDL-C lowering while maintaining tolerability STX-1200 surrogate achieved >95% Lp(a) reduction in non-human primates, without detectable off-target editing in primary human hepatocytes, reinforcing the potential for a potent and precise one-time Lp(a)-lowering therapy designed to recapitulate genetic protection of low Lp(a) Results reinforce Scribe’s approach to addressing a critical unmet need in cardiovascular care: ultra-long-acting therapies designed to sustainably and substantially lower atherogenic lipoproteins and empower patients to prevent disease before it develops ALAMEDA, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) — Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, reported updated preclinical data from its STX-1150 and STX-1200 programs at the American Heart Association (AHA) Scientific Sessions 2026. The findings bolster Scribe’s strategy to develop ultra-long-acting genetic medicines targeting key lipid drivers of atherosclerotic cardiovascular disease (ASCVD). Cardiovascular risk accumulates over decades of exposure to elevated atherogenic lipids, making early and sustained lipid lowering critical. The efficacy of existing LDL-C-lowering therapies depends on lifelong treatment persistence, but 50 to 70% of patients discontinue certain therapies within one year. Meanwhile, about one in five people have genetically elevated Lp(a), an independent and causal ASCVD risk factor with no approved therapies. Scribe’s STX-1150 and STX-1200 programs aim to address these challenges by translating the protective effects of naturally occurring human genetic variants into durable genetic medicines. “We believe that a majority of heart attacks could be prevented if patients and providers were able to proactively, easily, and sustainably reduce lipids that drive ASCVD,” said Benjamin L. Oakes, Ph.D., co-founder and CEO of Scribe Therapeutics. “Our AHA data reinforce the potential for purpose-built CRISPR medicines to transform chronic cholesterol management and bring us closer to our vision of making the protective benefits of human genetics accessible to millions of patients.” STX-1150: Epigenetic silencer sustains >50% LDL-C lowering for at least two years after a single therapeutically relevant dose STX-1150 is Scribe’s lead investigational CRISPR-based epigenetic silencing therapy, currently being evaluated in a first-in-human trial in adults with elevated LDL-C and increased cardiovascular risk. Utilizing Scribe’s proprietary Epigenetic Long-term X-Repressor (ELXR) technology, STX-1150 is designed to recapitulate the cardioprotective biology of individuals with naturally occurring PCSK9 loss-of-function variants by durably repressing PCSK9 transcription without cutting or permanently altering DNA. In a late-breaking presentation at AHA, Scribe reported that: A single administration of a STX-1150 prototype achieved up to 68% LDL-C reductions in non-human primates (NHPs), with >50% lowering sustained for two years at a therapeutically relevant dose.No off-target changes were detected and a GLP toxicology study identified no test-article-related adverse findings.STX-1150 showed ≥2 to 5-fold greater potency in human translational models compared to NHPs, supporting the potential for effective translation.In an additional NHP study, re-dosing of STX-1150 enabled progressively greater LDL-C lowering while maintaining tolerability. The findings demonstrate the potential for years of sustained LDL-C lowering from a single treatment with substantially reduced dosing burden compared with current therapies, while supporting the potential for repeat dosing. As previously announced, Scribe anticipates reporting initial clinical data from the single ascending dose portion of its Phase 1 trial of STX-1150 in the first half of 2027. STX-1200: Gene editor achieves saturating liver editing and >95% Lp(a) reduction in non-human primates with a single administration STX-1200 is an investigational CRISPR-CasX gene editing therapy designed to inactivate the LPA gene in hepatocytes through a single administration to durably lower circulating Lp(a). By reducing production of apolipoprotein(a) [Apo(a)], a key component of Lp(a), STX-1200 aims to recapitulate the protective biology of naturally occurring LPA-lowering variants. At AHA 2026, Scribe presented preclinical data demonstrating: A single administration of a STX-1200 surrogate achieved >80% hepatic LPA editing, associated with >95% reduction in circulating plasma Apo(a) at 10 weeks post-dose.A STX-1200 prototype achieved >95% serum Apo(a) reduction from a single low dose (125 nominated sites in primary human hepatocytes (PHHs), even at supersaturating doses. Taken together, the data support the potential for potent and precise Lp(a) lowering from a one-time treatment that aims to recapitulate the genetic protection of LPA-lowering variants. Continued development of STX-1200 is supported by a grant from the California Institute for Regenerative Medicine (CIRM). About Scribe Therapeutics Inc. Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The Company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding Scribe’s strategy, business plans and objectives; the therapeutic potential, safety, efficacy, durability, scalability and clinical or commercial prospects of Scribe’s product candidates and technologies; the design, initiation, enrollment, conduct, timing and results of preclinical studies and clinical trials; the timing of clinical data and other anticipated milestones; the advancement of STX-1150, STX-1200, and other programs; the potential for translation of STX-1150’s preclinical potency findings to humans and the potential for repeat dosing; and the expected use and benefits of CIRM funding are forward-looking statements. The words “aim,” “anticipate,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “target,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the risk that results of preclinical studies may not be predictive of results in clinical trials; the risk that the durability, potency and tolerability observed in preclinical models may not translate to humans; the risk that Scribe’s product candidates may cause undesirable side effects; and those described under the heading “Risk Factors” in Scribe’s filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026, and future reports that Scribe may file with the SEC. Except as required by law, Scribe undertakes no obligation to update any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events. Investor Contact:Investor Relations, Scribe Therapeuticsir@scribetx.com Media Contact:Thermal for Scribe Therapeuticsmedia@scribetx.com

AccurKardia Named a Rising Star Winner at the 2026 Digital Health Hub – Digital Health & AI Awards at HLTH USA

NEW YORK–(BUSINESS WIRE)– #Awards–AccurKardia, an ECG-led diagnostics software company, today announced that it has been named a winner at the 2026 Digital Health & AI Awards, presented by the Digital Health Hub Foundation at HLTH USA 2026 in Las Vegas. AccurKardia is one of three Rising Star winners in the Cardiometabolic, Obesity & Diabetes category. The Foundation selected 38 winners from more than 1,300 participating companies worldwide and announced them on November 16 at its Awards Grand

Conavi Medical Announces Five-Year Extension of Credit Facilities with Japan Lifeline

Extension to April 2032 enhances financial flexibility as Conavi advances U.S. commercialization of OCTIV™TORONTO, Nov. 18, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has entered into an amendment with Japan Lifeline Co., Ltd. (“Japan Lifeline”) extending the maturity of the Company’s existing senior secured credit facilities by five years, from April 2027 to April 2032. The extension better aligns Conavi’s debt maturity profile with its commercial development plans following FDA 510(k) clearance and the completion of its first U.S. commercial placement and clinical cases with the OCTIV™ hybrid imaging system. “Japan Lifeline has supported Conavi for more than a decade, and we appreciate its continued commitment as we advance commercialization,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “This extension gives us greater financial flexibility to build on our initial U.S. clinical and commercial milestones. Our focus is on expanding hospital placements, supporting physician adoption and generating additional clinical evidence demonstrating the value of hybrid imaging in coronary interventions.” The interest rate under the credit facilities will increase from 6.5% to 10% per annum; however, consistent with the existing terms of the credit facilities, Conavi is generally not required to make any interest payments until maturity.   Additional details regarding the amendment will be included in the Company’s regulatory filings on SEDAR+ at www.sedarplus.ca. About Conavi Medical Conavi Medical Corp. is a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures. Its OCTIV™ hybrid imaging system combines intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) to provide simultaneous, co-registered images of coronary arteries using a single imaging catheter. These complementary imaging modalities provide physicians with information to support treatment decisions during coronary interventions. For more information, visit www.conavi.com. Forward looking information This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging, the ability of Conavi’s hybrid imaging system to meet market needs and Conavi’s plans for expanding hospital placements, supporting physician adoption and generating additional clinical evidence. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contact Mark Quick, Chief Financial Officer | 416-483-0100Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com